




AUSTRALIAN AND NEW ZEALAND
HEAD & NECK
CANCER SOCIETY

ANZHNCS ASM 2024

FINAL PROGRAM




*Collaborating to Redefine the Landscape
of Head & Neck Cancer Care*

Australian and New Zealand Head & Neck Cancer Society
25th Annual Scientific Meeting

29 – 31 August 2024

Sofitel Melbourne on Collins **Melbourne Australia**

  #anzhnscasm24 | www.tinyurl.com/anzhnsc24



KEYTRUDA as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of patients with metastatic or unresectable recurrent HNSCC, and whose tumours express PD-L1 [Combined Positive Score (CPS) ≥ 1] as determined by a validated test.¹

KEYTRUDA is PBS listed for certain patients with advanced HNSCC²

Criteria apply,
see www.pbs.gov.au

SELECTED SAFETY INFORMATION

Precautions: Immune-mediated adverse reactions (ImARs), incl. severe and fatal cases, have occurred in patients receiving KEYTRUDA. These have included, but not limited to: pneumonitis, colitis, hepatitis, nephritis, endocrinopathies, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis and bullous pemphigoid), uveitis, myositis, Guillain-Barre syndrome, pancreatitis, encephalitis, sarcoidosis, myasthenic syndrome/myasthenia gravis (incl. exacerbation), myelitis, vasculitis, hypoparathyroidism, gastritis, haemolytic anaemia, myocarditis, pericarditis and pericardial effusion, peripheral neuropathy, sclerosing cholangitis, exocrine pancreatic insufficiency, solid organ transplant rejection and severe infusion reactions (hypersensitivity, anaphylaxis).¹

ImARs have occurred after discontinuation of treatment with KEYTRUDA. ImARs can affect more than one body system simultaneously.¹

Contraindications: None.¹

Adverse events: In KEYNOTE-048, adverse reactions that occurred in $\geq 10\%$ of patients who received KEYTRUDA monotherapy or KEYTRUDA in combination with platinum and 5-FU chemotherapy were: fatigue, pyrexia, mucosal inflammation, constipation, nausea, diarrhoea, vomiting, dysphagia, stomatitis, rash, pruritis, cough, dyspnoea, hypothyroidism, decreased appetite, weight loss, pneumonia, headache, dizziness, peripheral sensory neuropathy, myalgia, neck pain and insomnia. Refer to the Product Information for further safety information.¹

In individual studies of patients with HNSCC treated with KEYTRUDA as monotherapy (n=909) the incidence of hypothyroidism was 16.1% (all Grades) with 0.3% Grade 3. In patients with HNSCC treated with KEYTRUDA in combination with platinum and 5-FU chemotherapy (n=276) the incidence of hypothyroidism was 15.2%, all of which were Grade 1 or 2.¹

Please review full Product Information before prescribing,
available at www.msinfo.com.au/keytrudapi
or by scanning this QR code



5-FU: 5-fluorouracil. **CPS:** combined positive score. **HNSCC:** head and neck squamous cell cancer.

References: 1. KEYTRUDA Product Information, www.msinfo.com.au/keytrudapi.

2. Australian Government Department of Health. Pharmaceutical Benefits Scheme (PBS). Available at www.pbs.gov.au. Accessed March 2024.

ANZHNCS ASM 2024

29 – 31 August 2024

Sofitel Melbourne on Collins, Melbourne, Australia

Collaborating to Redefine the Landscape of Head & Neck Cancer Care



CONTENTS

Welcome	4
Keynote Speakers	5
Organising Committee.....	6
Executive Committee.....	6
Australian and New Zealand Head & Neck Cancer Society (ANZHNCS).....	6
Sponsors and Exhibitors	7
General Information	8
Business Meetings	10
Workshops	10
Official Functions	11
Final Program.....	12
Wednesday 28 August 2024.....	12
Thursday 29 August 2024.....	12
Friday 30 August 2024	14
Saturday 31 August 2024.....	18

ANZHNCS ASM 2024

29 - 31 August 2024

Sofitel Melbourne on Collins, Melbourne, Australia

Collaborating to Redefine the Landscape of Head & Neck Cancer Care



WELCOME

Dear Colleagues,

It is an honour to have you to join us for the 25th ANZHNCS Annual Scientific Meeting (ASM) held at the Sofitel Melbourne on Collins, 29 - 31 August 2024. A very exciting program has been put together by the wonderful organising committee.

The theme "***Collaborating to Redefine the Landscape of Head & Neck Cancer Care***" highlights our continued endeavours towards optimising patient outcomes through collaboration and ongoing interdisciplinary efforts that offers respect, expertise and inclusiveness. Head and neck treatment has evolved greatly over recent years as we move into an era of emerging new therapies such as immunotherapy, an era of redefining treatment algorithms and appropriate de-escalation, and most importantly, an era where more emphasis is placed on survivorship and patient long term functional needs. ANZHNCS ASM 2024 in Melbourne aims to bring together all disciplines (medical, dental and allied health alike) to collaborate, share advances in knowledge and focus on the crucial work that we all do.

We have a wonderful line up of invited guest speakers who will intrigue, inform and challenge us with their wealth of knowledge and experience. These speakers include international specialists Professor Renata Ferrarotto, Professor Clifton (David) Fuller, Professor Hisham Mehanna, Professor Heather Starmer and local guest speaker Professor June Corry presenting the 2024 ANZHNCS ASM Chris O'Brien Oration.

We would also like to thank and acknowledge our industry sponsors for 2024: Gold Sponsor - MSD; Silver Sponsor - Medison Pharma; Bronze Sponsors - Atos Medical, BioMeDent, GSK, KLS MARTIN AUSTRALIA, LifeHealthcare Distribution Pty Ltd, Lyka Smith, Prosperity Health; Scientific Session Sponsors - MSD and Replimune Group and Meeting Dinner Sponsor - GenesisCare. We encourage you to visit our industry colleagues in the exhibition during the breaks.

Melbourne is known for great coffee, excellent dining, iconic laneways, galleries, eye-catching street art and our famous weather; with four seasons in one day. We welcome you with much excitement, so please join us at ANZHNCS ASM 2024 and encourage you to enjoy what the wonderful city of Melbourne has to offer!

Best wishes,



Dr Kevin Nguyen
ANZHNCS ASM 2024 Convener

ANZHNCS ASM 2024

29 - 31 August 2024

Sofitel Melbourne on Collins, Melbourne, Australia

Collaborating to Redefine the Landscape of Head & Neck Cancer Care



KEYNOTE SPEAKERS

Keynote Speakers



Professor Renata Ferrarotto is a Professor and Director of Head and Neck Oncology Clinical Research of Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center. In this role, she dedicates time to patient care as well as to clinical and translational research.



Professor Clifton (Dave) Fuller is a radiation oncologist and Professor, Division of Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX. His research efforts are focused on novel imaging methodologies and applications in target delineation and normal tissue assessment in patients receiving head and neck radiotherapy.



Professor Hisham Mehanna is a Head & Neck Surgeon and the Deputy Pro-Vice Chancellor, Chair of Head and Neck Surgery, and Director of the Institute of Head and Neck Studies and Education, at the University of Birmingham, UK.



Professor Heather Starmer is a Speech-Language Pathologist and Board-Certified Specialist in Swallowing and Swallowing Disorders. She is a clinical Professor in the Department of Otolaryngology - Head & Neck Surgery at Stanford University and the Director of Head and Neck Speech and Swallowing Rehabilitation at the Stanford Cancer Center.

2024 ANZHNCS Chris O'Brien Orator



Professor June Corry is a radiation oncologist and a founding member and past president of the ANZHNCS and IAOO societies, a previous executive member of the TROG Cancer Research Group, previous Chair of the TROG ANROTAT NPC committee. Professor Corry is based in Melbourne, Victoria.

International Invited Speakers



Dr Ashish Patel (*sponsored by KLS MARTIN AUSTRALIA PTY LTD*) is a fellowship-trained Head and Neck Surgical Oncologist and Reconstructive Microsurgeon. He obtained his Medical and Dental degrees at New York University and completed Fellowships in Head and Neck Oncology and Microvascular Reconstruction at Providence Cancer Institute in Portland, OR.



Dr Sue Yom is the Vice Chair of Strategic Advisory and the Irwin Mark Jacobs and Joan Klein Jacobs Distinguished Professor in the Departments of Radiation Oncology and Otolaryngology Head and Neck Surgery at the University of California San Francisco. She has served on expert panels and scientific organising committees for numerous professional societies.

To view all speaker biographies, please view the meeting website at www.tinyurl.com/anzhnscs24.

ANZHNCS ASM 2024

29 – 31 August 2024

Sofitel Melbourne on Collins, Melbourne, Australia

Collaborating to Redefine the Landscape of Head & Neck Cancer Care



ORGANISING COMMITTEE

Convener

Dr Kevin Nguyen – Otolaryngology, Head & Neck Surgeon, Head & Neck Reconstructive Surgeon
Peter MacCallum Cancer Centre, The Royal Melbourne Hospital, Eastern Health,
Melbourne, VIC

Committee Members

Dr Jacqui Frowen – Speech Pathologist, Peter MacCallum Cancer Centre, Melbourne VIC

Dr Annette M. Lim – Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, VIC

Dr Matthew Magarey – ENT Head & Neck Surgeon, Peter MacCallum Cancer Centre, Melbourne, VIC

Associate Professor Sweet Ping Ng – Radiation Oncologist, Austin Health, Melbourne, VIC

Associate Professor Felix Sim – Oral and Maxillofacial/Head and neck surgeon, Melbourne Health
and Barwon Health, Melbourne, VIC

Dr Alesha A. Thai – Medical Oncologist, Austin Health and Peter MacCallum Cancer Centre,
Melbourne, VIC

Ms Meiling Zhou – Nurse consultant, Peter MacCallum Cancer Centre, Melbourne, VIC

EXECUTIVE COMMITTEE

Professor Eng Hooi Ooi – President | Otolaryngology Head & Neck Surgeon

Dr Julia Crawford – Vice President | Otolaryngology Head & Neck Surgeon

Professor Camile Farah – Treasurer | Oral Medicine Specialist

Dr Aoife McGarvey – Secretary | Physiotherapist

Dr Tsien Fua – Immediate Past President | Radiation Oncologist

Dr Eric Khoo – Executive | Radiation Oncologist

Associate Professor Felix Sim – Executive | Oral Maxillofacial Surgeon

Mr Glen Ramos – Executive | Independent Advisor

Ms Tracey Nicholls – Executive | Nurse Practitioner ENT

Dr Merran Findlay – Executive | Executive Research Lead | Clinical Associate Professor |
Oncology Dietetics Clinical Research Fellow

Associate Professor Kerwin Shannon – Executive | Australian Research Foundation Chair |
Head and Neck Surgeon

Professor Swee Tan – Executive | New Zealand Research Foundation Chair | Plastic & Reconstructive

AUSTRALIAN AND NEW ZEALAND HEAD & NECK CANCER SOCIETY (ANZHNCS)

Early in 1998, a number of head and neck oncologists from the disciplines of surgery, radiation oncology and medical oncology met in Sydney to discuss the feasibility of establishing a multidisciplinary head and neck cancer society. A working party was formed and following a number of meetings, invitations were sent to individuals in these three specialties to become foundation members of the Australian and New Zealand Head & Neck Cancer Society.

The initial business meeting was held on December 9, 1998 and at that time there were 60 foundation members. The Society adopted as its Constitution the Model Rules for Associations published by the Department of Fair Trading in NSW and the members agreed that their principal objectives would be to promote the practice of head and neck oncology, to educate medical colleagues and the public about our specialty, to foster research and to seek optimal treatment outcomes for our patients.

For more information about the ANZHNCS, please visit: <https://anzhnscs.org/about/what-is-the-anzhnscs/>

ANZHNCS ASM 2024

29 - 31 August 2024

Sofitel Melbourne on Collins, Melbourne, Australia

Collaborating to Redefine the Landscape of Head & Neck Cancer Care



SPONSORS AND EXHIBITORS

Sponsors

Gold Sponsor:



Silver Sponsor:



Bronze Sponsors:



LifeHealthcare®

Scientific Session
Sponsors:



Meeting Dinner
Sponsor:



Exhibitors

3-D Matrix Medical Technology
Ambu Australia
ANZHNCS & HANCA
Atos Medical
BioMeDent
Avant Mutual & Doctors
Health Fund
GSK
INTEGRA LIFESCIENCES

i-scribe (Akuru Pty Ltd)
KLS MARTIN AUSTRALIA
PTY LTD
LifeHealthcare Distribution
Pty Ltd
Lyka Smith
MAIN MEDICAL
Medison Pharma
MIPS

MSD
Nestle Health Science
PolyNovo
Prosperity Health
Replimune
Samson Medical Technologies
Southern Implants Australia
STRYKER
TRISTEL

ANZHNCS ASM 2024

29 - 31 August 2024

Sofitel Melbourne on Collins, Melbourne, Australia

Collaborating to Redefine the Landscape of Head & Neck Cancer Care



GENERAL INFORMATION

Date and Venue

The ANZHNCS ASM 2024 will be held at Sofitel Melbourne on Collins, Melbourne, VIC from Thursday 29 to Saturday 31 August 2024. For further information please visit <https://www.sofitel-melbourne.com.au>.

Registration Desk

The registration desk will be located in the Grand Ballroom Foyer and will be open during the following hours:

Thursday 29 August 2024 7:00am - 5:00pm

Friday 30 August 2024 7:00am - 5:00pm

Saturday 31 August 2024 8:00am - 11:00am

Public transport

Melbourne offers free tram rides within the city center. To use public transport outside of the free tram zone, you need to purchase a Myki card. You can purchase a Myki card from retail outlets displaying the Myki sign, visitor centres and at train stations. To view the Melbourne CBD Free Tramzone Map, [click here](#).

Parking

Please refer to the Sofitel Melbourne on Collins website below for information on parking and traveling to the venue: <https://www.sofitel-melbourne.com.au/around-the-hotel/locationandservices/>

Intention to Photograph

Please be advised that photographs may be taken during the meeting and reproduced by the meeting organiser.

These photos may be used for the following purposes:

- Projection onsite
- Reporting on the meeting online
- Marketing a future meeting, including online and hard copy publications
- Publishing in RACS/ANZHNCS publications

If you do not wish to be included in a photograph, please advise the photographer.

Name Badges

Your name badge is essential for entry into scientific sessions. Please collect your name badge from the registration desk prior to entering the sessions.

Internet Facilities

Wireless internet will be available throughout the meeting. Details will be made available onsite.

Registration Information

Full registration includes:

- Access to scientific sessions
- Access to the industry exhibition
- Morning and afternoon tea refreshments in accordance with the program
- Lunch in accordance with the program
- Welcome Reception ticket (Thursday 29 August 2024)*
- Meeting Dinner ticket (Friday 30 August 2024)*

**The Welcome Reception and Meeting Dinner are not included in day registration categories. Delegates have the option to register in a category that includes one reduced cost Meeting Dinner ticket. Tickets which are not included in your registration category must be purchased separately.*

One day registration includes:

- Access to scientific sessions (as applicable)
- Access to the industry exhibition
- Morning and afternoon tea refreshments in accordance with the program
- Lunch in accordance with the program

Concessional Registration

Concessional registration is available to nurses, allied health professionals, trainees and medical students.

Dress

Scientific Sessions:

Business attire or smart casual

Welcome Reception:

Business attire or smart casual

Meeting Dinner:

Lounge suit/cocktail attire. In celebration of the 25th ANZHNCS ASM, please come dressed in your favourite era with a touch of silver!

Posters

Posters will be displayed in the Grand Ballroom Foyer and will be available for viewing throughout the meeting.

ANZHNCS ASM 2024

29 - 31 August 2024

Sofitel Melbourne on Collins, Melbourne, Australia

Collaborating to Redefine the Landscape of Head & Neck Cancer Care



GENERAL INFORMATION (cont'd)

Certificate of Attendance

A certificate of attendance will be circulated electronically at the conclusion of the meeting.

Continuing Professional Development (CPD)

This educational activity has been approved in the RACS CPD Program. RACS Fellows, Specialist International Medical Graduates (SIMGs) and surgeons participating in the RACS CPD Program can claim one point per hour in Educational Activities (maximum 16 points).

RACS Fellows, participation in this activity will be entered into your RACS CPD which can be accessed through ehub if you provided your RACS ID when registering.

Awards

- Best Overall Oral Presentation
- Best Overall Poster Presentation

The above-mentioned prizes will be awarded at the meeting. Entries are assessed during the meeting and then announced at the close of the meeting.

Industry Exhibition

The industry exhibition will be held in the Sydney/Perth Ballroom, Sofitel Melbourne on Collins. Delegates will have the opportunity to visit industry booths in the program breaks.

Speakers' Support

Presenters are required to provide an electronic PowerPoint copy of their presentation to the Speakers' Support desk at the meeting at least 1 hour prior to the commencement of their session. Speakers' Support is located at the back of the room in the Latrobe Ballroom and the Brisbane Ballroom Room at Sofitel Melbourne on Collins.

A technician will be available at the Speakers' Support desk one hour prior to the commencement of the first session and during the catering breaks from Thursday 29 August to Saturday 31 August 2024.

Dietary Requirements

Please note that the venue is responsible for all catering at the meeting and ANZHNCS/RACS does not inspect or control food preparation areas or attempt to monitor ingredients used. You should contact the venue directly for all special dietary requirements during the event, irrespective of whether details have been

provided to ANZHNCS/RACS. If ANZHNCS/RACS requests information about your dietary requirements for a specific event ANZHNCS/RACS will endeavour to forward the information provided to the venue (time permitting). ANZHNCS/RACS will not retain information provided for future events, so you must verify your requirements for each event. Even if information is requested or provided, ANZHNCS/RACS takes no responsibility for ensuring that the venue acknowledges your dietary requirements or that these requirements can be met. In all cases you must verify for yourself that your dietary requirements have been met and ANZHNCS/RACS refutes any and all liability for any failure to adequately provide your special dietary requirements or any consequential damage resulting from such failure.

Atos

Breathing-Speaking-Living
atosmedical.com

Atos Medical develops and sells medical devices that improve quality of life for people living with a neck stoma in over 90 countries.

Since our foundation in 1986, we have cemented ourselves as the leaders in neck stoma care, and today our business includes innovative products in laryngectomy and tracheostomy care to help people breathe, speak and live well.

We want to create the best experience for our customers, and we know this involves more than first-rate product development, which is why clinical research and education of both professionals and patients are integral parts of our business. We are passionate about making life easier for people living with a neck stoma, by providing personalized care and innovative solutions.

We are a truly global organization with Swedish roots made up of about 1200 employees. Atos Medical is a part of Coloplast A/S.

ANZHNCS ASM 2024

29 – 31 August 2024

Sofitel Melbourne on Collins, Melbourne, Australia

Collaborating to Redefine the Landscape of Head & Neck Cancer Care



BUSINESS MEETINGS

ANZHNCS Executive Committee Meeting

(Executive Committee Members only)

Date: Wednesday 28 August 2024

Time: 5:00pm – 6:30pm

Venue: Victoria Suites 1,
Sofitel Melbourne on Collins

ANZHNCS Annual General Meeting (AGM)

(ANZHNCS Members only)

Date: Friday 30 August 2024

Time: 5:00pm – 5:45pm

Venue: Brisbane Ballroom,
Sofitel Melbourne on Collins

WORKSHOPS

Jaw in a Day: An instructional course in maxillo-mandibular reconstruction and dental rehabilitation

Date: Wednesday 28 August 2024

Time: 8:00am – 7:00pm

Venue: Royal Australasian College of Surgeons,
East Melbourne

Invited Speaker: **Dr Ashish Patel (United States)**

Hosted by **KLS martin**
GROUP

This full day course provides surgeons and prosthodontists didactic learning and hands-on lab experience to deliver immediate dental rehabilitation at the time of reconstruction.

The course is intended for Oral & Maxillofacial Surgeons, Head and Neck Surgeons, ENT surgeons, Plastic Surgeons and Prosthodontists.

For more information, including a full course outline, visit the [course website here](#).

Custom Silicone Colour Matching for Facial Prosthetics

Date: Saturday 31 August 2024

Time: 1:00pm – 5:00pm

Venue: TBC, Melbourne


Guest Speaker: **Sophie Fleming (Sydney)**

Hosted by **BioMeDent.**
Specialised Dental & Medical Solutions

Dive into the art and science of matching silicone colours to create lifelike facial prosthetics. This hands-on course covers advanced techniques in colour theory, pigment blending, silicone choice and application methods.

Learn to meticulously match skin tones utilising the Spectromatch digital system as well as traditional technique. Perfect for prosthetists, clinicians and anyone seeking expertise in creating natural-looking facial prosthetics.

For more information, including a full course outline, view the [course website here](#).




BioMeDent.
Specialised Dental & Medical Solutions

INNOVATIVE SOLUTIONS
FOR DENTAL AND MEDICAL
PROFESSIONALS



Our goal is to
collaborate with
you to improve the
results for your
patients.






TECHNOVENT

Technovent specializes in developing and manufacturing magnetic retention systems for dental and craniofacial use. They produce high-quality silicone elastomers, adhesives, colors, and the MagnaCap magnetic retention system for craniofacial prostheses.

Some of the agencies we represent







www.biomedent.com.au 1300 792 624

ANZHNCS ASM 2024

29 – 31 August 2024

Sofitel Melbourne on Collins, Melbourne, Australia

Collaborating to Redefine the Landscape of Head & Neck Cancer Care



OFFICIAL FUNCTIONS

Welcome Reception

Date: Thursday 29 August 2024

Time: 5:00pm – 7:00pm

Venue: Sydney/Perth Ballroom,
Sofitel Melbourne on Collins

Cost: Included for full registration categories*,
Bookings essential.

Additional tickets: \$70.00 per person

**Subject to availability at the time of booking.*

Network with academic faculty, industry and fellow colleagues whilst celebrating the opening of this important meeting.

Meeting Dinner

Date: Friday 30 August 2024

Time: 7:00pm – 11:00pm

Venue: Fitzroy Ballroom,
Sofitel Melbourne on Collins

Cost: \$150.00 per person**, bookings essential.

Dress: In celebration of the 25th ANZHNCS ASM, please come dressed in your favourite era with a touch of silver!

***Delegates have the option to register in a category that includes one reduced cost Meeting Dinner ticket. Additional Meeting Dinner tickets can be purchased for accompanying persons at full price. Subject to availability at the time of booking.*

Enjoy a three-course dinner and entertainment with colleagues and friends.



NOW PBS LISTED FOR:^{1,2}

Monotherapy[‡] or combination therapy[§] for stage IV (metastatic) non-small cell lung cancer (mNSCLC)²

[‡]mNSCLC without EGFR, ALK or ROS1 aberrations, PD-L1 expression (TPS) $\geq 50\%$ ^{1,2}

[§]In combination with platinum-based chemotherapy in mNSCLC without EGFR, ALK or ROS1 aberrations, regardless of PD-L1 expression^{1,2}

Authority required (streamlined), further eligibility criteria apply[†]

Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC)^{*2}

^{*}Unsuitable for curative surgical resection and curative radiotherapy²

Authority required, further eligibility criteria apply[†]

[†]Please refer to the PBS Schedule for full eligibility criteria.

PBS Information: Authority Required (STREAMLINED) or Authority Required. Please refer to PBS Schedule for full Authority information.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.



Please review Product Information before prescribing. **Scan QR code for full LIBTAYO Product Information.**

Alternatively, visit <https://www.medisopharma.com.au/products/LibtayoPI>

or contact Medison Medical Information on 1800 566 020.

ALK=anaplastic lymphoma kinase; CSCC=cutaneous squamous cell carcinoma; EGFR=epidermal growth factor receptor; mNSCLC=metastatic non-small cell lung cancer; NSCLC=non-small cell lung cancer; PD-L1=programmed cell death ligand 1; ROS1=c-ROS proto-oncogene 1; TPS=tumour proportion score.

References: 1. LIBTAYO (cemiplimab) Approved Product Information. 2. Australian Government, Department of Health and Aged Care. The Pharmaceutical Benefits Scheme. www.pbs.gov.au/medicine/item/13152F-13159N-13161Q-13169D (accessed June 2024).

MEDISON

LIBTAYO® is a registered trademark of Regeneron Pharmaceuticals, Inc. ©2024 Medison Pharma Australia Pty Ltd. ABN 19 659 723 403.
1 Bligh Street, Sydney, NSW 2000, Australia. www.medisopharma.com.au. AUS-RGN-P-240030. Ward7 MDLI33427M. Date of preparation: June 2024.

ANZHNCS ASM 2024

29 – 31 August 2024

Sofitel Melbourne on Collins, Melbourne, Australia

Collaborating to Redefine the Landscape of Head & Neck Cancer Care



FINAL PROGRAM

Wednesday 28 August 2024

8:00am – 7:00pm **Pre-Meeting Workshop: Jaw in a Day: An instructional course in maxillo-mandibular reconstruction and dental rehabilitation**
 Royal Australasian College of Surgeons, East Melbourne
 Hosted by **KLS martin GROUP**
Dr Ashish Patel

11:20am

Facing the shadows: Insights from prospective data and clinician perspectives on Fear of Cancer Recurrence
Dr Lachlan McDowell

11:40am

Availability and characteristics of support groups for people with head and neck cancer in Australia
Dr Rebecca Venchiarutti

11:50am

Patient Panel Discussion: Fear of recurrence
Lead by Julie McCrossin

Thursday 29 August 2024

8:30am – 10:30am **Plenary Session 1: Collaborating to define the landscape of head and neck cancer care**
 Latrobe Ballroom

Proudly sponsored by  **MSD**

8:30am ASM welcome & Acknowledgment of country
Dr Kevin Nguyen

8:40am ANZHNCS Research Foundation
A/Prof Kerwin Shannon

8:50am Latest updates from Head and Neck Cancer Australia (HANCA)
Nadia Rosin (HANCA)

9:00am Major advances in HNC in the last 2 decades – And lessons learnt
Prof June Corry – introduced by A/Prof Bernard Lyons

9:30am Neoadjuvant approaches in CSCC and mucosal HNSCC
Prof Renata Ferrarotto

10:00am The evolving role of Speech – Language pathology in H&N cancer
Prof Heather Starmer

10:30am – 11:00am **Morning tea with industry**
 Sydney/Perth Ballroom

11:00am – 12:30pm **Concurrent Session 2A: Improving survivorship outcomes: Fear of recurrence**
 Latrobe Ballroom

11:00am New paradigms for post-treatment surveillance
Prof Hisham Mehanna

11:00am – 12:30pm

Concurrent Session 2B: Revolutionising treatment paradigms with new approaches and AI
 Brisbane Ballroom

11:00am

The pipe dream of international head and neck cancer trials: Becoming a reality for NRG-TROG
Prof Sue Yom

11:20am

From machine learning to uncertainty-aware digital twins: Current & future AI applications in radiation oncology
Prof David Fuller

11:40am

Exploring the potential of the HoloLens 2: The future of mentored support for rural/remote speech pathology management of laryngectomy patients
Dr Clare Burns

11:50am

Actionable genomic variants in sinonasal epithelial malignancy and their clinical significance
Dr Rhea Darbari Kaul

12:00pm

Bio-printed adipose-derived mesenchymal stem cells for engineering vascularized bone tissue within an in vivo printed thermoplastic bioreactor
Dr D S Abdullah Al Maruf

12:10pm

Australian experience with new approaches for Mx CSCC (elderly, translational)
Dr Luke McLean

12:20pm

GPS for the Mouth
Dr Tami Yap

FINAL PROGRAM (cont'd)

12:30pm - 1:30pm **Lunch with industry**
Sydney/Perth Ballroom

1:30pm - 3:00pm **Concurrent Session 3A:
Collaborating to assess and
manage toxicities to improve
patient outcomes**
Latrobe Ballroom

1:30pm Strategies for improving
swallowing outcomes during
radiotherapy
Prof Heather Starmer

1:50pm Using MRI to identify swallow-
related tissue changes post
treatment
A/Prof Laurelie Wishart

2:05pm Taste changes and dietary intake
in patients with head and neck
cancer post chemoradiation
according to genetically
determined Taster Status
Dr Teresa Brown

2:20pm SPECT: A novel methodology
to quantify aspiration, airway
clearance and utility of EMST
following head and neck cancer
A/Prof Julia Maclean

2:30pm Venous thromboembolism
prophylaxis in reconstructive
head and neck tumour patients:
A 12 year retrospective cohort
study comparing subcutaneous
unfractionated heparin
administered every 8 hours versus
every 12 hours
Dr Jevan Cevik

2:40pm "What matters to you?" - The
value of PROMS and identifying
unmet need to enhance head and
neck cancer rehabilitation
Prof Justin Roe

1:30pm - 3:00pm **Concurrent Session 3B:
Optimising functional outcomes
with facial nerve sacrifice**
Brisbane Ballroom

1:30pm Immediate reconstruction in facial
nerve sacrifice
Dr James Finkenmeyer

1:45pm Improving the outcome of facial
nerve management through
collaboration PROM
**A/Prof Hubert Low and
Dr Emma Charters**

2:15pm Physiotherapy to aid facial nerve
recovery
Keegan Bow

2:30pm Delayed facial nerve
reconstruction
A/Prof Catherine Meller

2:45pm Trismus after facial reanimation
surgery: Incidence and treatment
Dr Lachlan Jackson

2:52pm Implantable hearing devices
following head and neck cancer
treatment
Dr Matthew Kwok

3:00pm - 3:30pm **Afternoon tea with industry**
Sydney/Perth Ballroom



**Break free from the
microscope with
Synaptive Robotic Exoscope.**

©2024 LifeHealthcare Distribution Pty Ltd. ®/TM denote trademarks of LifeHealthcare Distribution Pty Ltd and its affiliates. LHC0590. ABN 30 117 449 911. L8, 15 Talavera Road, North Ryde NSW 2113 Australia. www.lifehealthcare.com.au

ANZHNCS ASM 2024

29 - 31 August 2024

Sofitel Melbourne on Collins, Melbourne, Australia

Collaborating to Redefine the Landscape of Head & Neck Cancer Care



FINAL PROGRAM (cont'd)

3:30pm - 5:00pm **Plenary Session 4: Will we ever de-escalate treatment?**
Latrobe Ballroom

Proudly sponsored by:  Replimune®

3:30pm Adaptive & biomarker driven replanning applications in head and neck cancer

Prof Clifton (Dave) Fuller

4:00pm What does the largest ever cross-sectional study on patient-reported outcomes tell us about long term swallowing after modern (chemo)radiotherapy

Dr Jacqui Frowen

4:10pm Sensorineural hearing outcomes in patients on TROG12.01 trial of weekly Cisplatin+RT vs Weekly Cetuximab+RT in HPV-Positive oropharyngeal SCC (SHOUT)

A/Prof Laurelie Wishart

4:20pm Tinnitus association of Victoria: Why and how support groups help

Karen Enshaw

4:30pm De-escalation for HPV+OPC - is it time to change tack?

Prof Hisham Mehanna

5:00pm - 7:00pm **Welcome Reception**
Sydney/Perth Ballroom

8:17am

Evaluating a shared care model supporting regional/rural patients with head and neck cancer to access local speech pathology care

Corey Patterson

8:25am

Optimal models of care for follow-up of survivors of head and neck cancer in rural area; A systematic review

Dr Rebecca Venchiarutti

8:35am

Panel Discussion: How a model of shared care for head and neck cancer survivors might look in practice: Challenges and methods to provide care/shared care

Dr Albert Tiong, Dr Eliza Tweddle, Dr Eva Yabe

Friday 30 August 2024


8:00am - 8:50am **Breakfast Session 5A: Championing areas of unmet need: Rural and regional patients**
Latrobe Ballroom

8:00am HN care from a regional based specialist - What are the challenges

Dr Eliza Tweddle

8:10am Health care utilisation and unmet needs in survivors of head and neck cancer in regional/remote Australia: A cross-sectional survey

Dr Poorva Pradhan



ANZHNCS ASM 2024

29 - 31 August 2024

Sofitel Melbourne on Collins, Melbourne, Australia

Collaborating to Redefine the Landscape of Head & Neck Cancer Care



FINAL PROGRAM (cont'd)

8:00am - 8:50am	Breakfast Session 5B: Head and neck nurse specialists and allied health taking the lead <i>Brisbane Ballroom</i>	9:55am	Improving the outcomes for patients with tongue cancer through clinical and laboratory research Prof David Wiesenfeld
8:00am	Nurse Practitioner model of care Tracey Nicholls	10:10am	How does tilmanocept based lymphoscintigraphy measure up against sulfur colloid for sentinel node biopsy in early oral squamous cell cancer and melanoma? An Australian perspective Dr Giuleta Jamsari
8:10am	3 Flap, Free Flap Fridays in Da House: The Lifehouse Experience 2014-2024 Catriona Froggatt	10:20am	Prevalence of risk behaviours in oral cavity and oropharyngeal cancers Thu Thu Win Myint
8:20am	Improving access to shared consumer experiences to support people across their laryngectomy journey Belinda Lehn	10:30am - 11:00am	Morning tea with industry <i>Sydney/Perth Ballroom</i>
8:30am	How a weekend speech pathology service impacts clinical outcomes within an Enhanced Recovery After Surgery Program for patients undergoing head and neck surgery with free flap reconstruction Lauren Davies	11:00am - 12:30pm	Concurrent Session 7A: Championing areas of unmet need <i>Latrobe Ballroom</i>
8:40am	Co-design of an app-based monitoring and support model of care for patients on Home Enteral Nutrition (HEN) Jane Stewart	11:00am	Salivary gland tumors: Championing novel approaches and unmet need Prof Renata Ferrarotto
9:00am - 10:30am	Plenary Session 6: Collaborating to address the rise in oral cavity cancer <i>Latrobe Ballroom</i>	11:20am	Redifferentiation Therapy for Radio-iodine Refractory Thyroid Cancer - the I-FIRST study Andrew Scott
9:00am	Epidemiology and inequities in oral cancer Dr Ankur Singh	11:35am	The use of ultra high-resolution MRI for the assessment of cranial neuropathies in base of skull tumours Wallace Walker
9:12am	Advancing nutrition in head and neck cancer: From innovative research to clinical practice Prof Judy Bauer	11:42am	In vitro study: Anti-tumour activity of repurposed iron-chelating and anti-malarial drugs in three-dimensional cell cultures of head and neck cancer Dr Kenny Chitcholtan
9:25am	Approaches when cancer extends beyond the oral tongue Dr Andrew Foreman	11:50am	Reirradiation: The Anna Karenina principle Prof Clifton (Dave) Fuller
9:40am	Liquid biopsy in oral cancer diagnosis and management Dr Omar Breik		



FINAL PROGRAM (cont'd)

12:10pm	Health professionals' priorities for a First Nations Australians' head and neck cancer (HNC) pathway Stephanie Ng
12:20pm	Final analysis of a prospective study evaluating sexual health, facial appearance, and appearance distress in patients with human papillomavirus-associated oropharyngeal cancer (HPVOPC) patients treated with (chemo)radiation (CRT/RT) Dr Lachlan McDowell
11:00am - 12:31pm	Concurrent Session 7B: Optimizing dental outcomes for head and neck cancer patients Brisbane Ballroom
11:00am	Patient perspective on barriers and challenges in accessing dental care during cancer treatment Invited patient representative
11:10am	Dental care and maintenance in the long term - What is the landscape like in Australia, how can we do better A/Prof Mathew Lim
11:25am	What does a conventional denture look like versus implant supported Dr Simon Watson
11:40am	Pre-surgical dental considerations A/Prof Dale Howes
11:55am	A radiation oncologist's perspective barriers in implementing routine dental screening pre RT Dr Madhavi Chilukuri
12:10pm	The quality of life impact of maxillofacial reconstruction with dental implants: A systematic review Dr Simra Azher
12:17pm	Early health-related quality of life after jaw-in-a-day surgery Dr Yu Jin Jeong

12:24pm	Micro costing analysis of dental prosthetics in head and neck reconstruction Dr Alex D'jamirze
12:30pm - 1:30pm	Lunch with industry Sydney/Perth Ballroom
1:30pm - 3:01pm	Concurrent Session 8A: Multidisciplinary approaches to improving pre-treatment determinants Latrobe Ballroom
1:30pm	Cancer care equity and electronic social determinants of health reporting Elizabeth Crone

LYKA SMITH
Australian Innovation

Australian Made
Local Engineers
3-5 Day Turnaround

Lyka Smith is an Australian medical device company specialising in craniomaxillofacial solutions.

Headquartered in Melbourne, Lyka Smith is dedicated to advancing patient-specific care for plastic and maxillofacial surgeons. We take pride in delivering tailor-made patient-specific devices with unmatched precision and a rapid turnaround time of 3-5 days from surgeon approval.

Driven by innovation and a commitment to enhancing patient outcomes, Lyka Smith stands as a leader in craniomaxillofacial advancements, offering a seamless integration of cutting-edge technology and personalized medical solutions.

OUR RECONSTRUCTION SERVICES:

- VIRTUAL SURGICAL PLANNING
- INTRAORAL SCANNING
- DENTURE MODELS FOR OCCLUSAL PLANNING
- PATIENT SPECIFIC PLATES
- CUSTOM SURGICAL GUIDES FOR MANDIBLE, FIBULA, ILLIAC CREST & SCAPULA
- DENTAL IMPLANT PLANNING FOR IMMEDIATE PLACEMENT
- TEMPORARY DENTAL PROSTHESES

www.lykasmith.com

ANZHNCS ASM 2024

29 - 31 August 2024

Sofitel Melbourne on Collins, Melbourne, Australia

Collaborating to Redefine the Landscape of Head & Neck Cancer Care



FINAL PROGRAM (cont'd)

1:50pm	Enhanced recovery after surgery with prehabilitation (ERAS+) program reduces length of stay (LOS) following major head and neck surgery with free flap (FF) reconstruction: An uncontrolled before and after study Carrie Service	1:40pm	Changing faces: The evolution of facial prosthetics at The Royal Melbourne Hospital to continually drive for better Jessica Willason
2:00pm	Prehabilitation for head and neck cancer patients planned for radiotherapy Ella Sexton (Psychologist) & Hannah Ray (Dietician)	1:45pm	Prosthetic retention: Time for a more attractive option A/Prof Martin Batstone
2:15pm	Embedding sexuality discussion in cancer care Eliza Bailey (Sexologist)	1:55pm	Advances in 3D printing technology in facial prosthetics Dr Chen Chen
2:30pm	Prognostic impact of class I and class II sarcopenia in patients with head and neck cancer: Validation in an Australian cohort Clinical A/Prof Merran Findlay	2:10pm	Panel Discussion: MDT
2:40pm	Implementing an evidenced-based model of pre-operative nutrition care in patients undergoing oral cavity reconstruction surgeries for head and neck cancer: A feasibility study Shane McAuliffe	3:00pm - 3:30pm	Afternoon tea with industry Sydney/Perth Ballroom
2:47pm	Exploring use of Fried's Frailty Phenotype (FFP) for assessing frailty in head and neck patients in a resource constrained setting Dr Vidisha Tuljapurkar-Bhujbal		
2:54pm	Lymph node yield following neck dissection for cutaneous SCC. Is there a benefit for targeted approach? Dr Navid Ahmadi		
1:30pm - 3:00pm	Concurrent Session 8B: Facing forward - The Past, Present and Future of facial prosthetics Brisbane Ballroom		
1:30pm	Functional and quality of life outcomes following maxillomandibular reconstruction: The Chris O'Brien Lifehouse experience of clinical utility and longitudinal outcomes Dr Masako Dunn		

Complimentary Financial Health check meeting

At Prosperity we pride ourselves on being the medical sector's financial specialists.

Reduce tax, drive the success of your practice, protect your assets and grow your investments - all with the help of Prosperity Health.

Visit us at **Stand 12** to complete our Financial Health check and go into the draw to win magnum of Moët.

Your prosperity is our business.

ANZHNCS ASM 2024


29 - 31 August 2024

Sofitel Melbourne on Collins, Melbourne, Australia

Collaborating to Redefine the Landscape of Head & Neck Cancer Care



FINAL PROGRAM (cont'd)

3:30pm - 5:00pm	Plenary Session 9: New insights into CSCC - Can we work together? <i>Latrobe Ballroom</i> <i>Proudly sponsored by</i>  MSD	9:40am	Identification of prognostic groups beyond AJCC staging to facilitate investigation of optimal treatment strategies for HPV oropharyngeal cancer Prof Danny Rischin
3:30pm	The De-squamate Trial A/Prof Rahul Ladwa	9:55am	Oropharyngeal SCC radiology Dr Robyn Cassambouy
3:40pm	Just because you're exhausted doesn't mean I will toss you out A/Prof Bruce Ashford	10:10am	The evolution of TORS and the dawn of the single port robot: A review of our 5 year experience highlighting technical advantages as well as promising future surgical applications A/Prof Hari Jeyarajan
3:50pm	The DISCERN neoadjuvant immunotherapy trial for CSCC: Preliminary surgical perspectives Dr Bryce Jackson and Dr Peter Lion	10:20am	A salivary biopsy for the detection of HPV16 SNPs for patient risk stratification Ha Ngoc Tran
4:10pm	Radiation oncology in the immunotherapy era Prof Sandro Porceddu	9:00am - 10:30am	Concurrent Session 10B: Advancing reconstruction to improve functional outcomes <i>Brisbane Ballroom</i>
4:25pm	Panel Discussion: MDT	9:00am	Advances in lower lip reconstruction Dr Jeremy Wilson
5:00pm - 5:45pm	ANZHNCS Annual Scientific Meeting (ANZHNCS members only) <i>Brisbane Ballroom</i>	9:10am	Advances in approaches for jaw in a day Prof Jonathan Clark
7:00pm - 11:00pm	Meeting Dinner In celebration of the 25th ANZHNCS ASM, please come dressed in your favourite era with a touch of silver! <i>Fitzroy Ballroom</i>	9:25am	Maxillary and mandibular reconstruction: Pitfalls and lessons learnt Dr Ashish Patel

Saturday 31 August 2024

9:00am - 10:30am	Concurrent Session 10A: New approaches and considerations in oropharyngeal carcinomas <i>Latrobe Ballroom</i>	9:40am	Optimising outcomes in pharyngeal and laryngeal reconstruction Dr Sam Dowthwaite
9:00am	Predictive biomarkers for oropharyngeal cancer - Do we need any more? Prof Hisham Mehanna	9:55am	Collaborative approaches to head and neck reconstruction Dr James Wykes
9:20am	Detecting HPV through liquid biopsies: Challenges and considerations for clinical applications Dr Stephen Wong	10:05am	In-vivo evaluation of a novel bioactive synthetic graft for skeletal and soft tissue reconstructive surgery A/Prof Sydney Ch'ng



FINAL PROGRAM (cont'd)

- 10:15am A cost-minimisation analysis between in-house and commercial virtual surgical planning for maxillary and mandibular reconstruction
Dr George Petrides
- 10:22am A novel protocol of oncological mandibular reconstruction to reduce the time to dental restoration
Dr Edwin Morrison
- 10:30am - 11:00am **Morning tea with industry**
Sydney/Perth Ballroom
- 11:00am - 12:45pm **Plenary Session 11: Collaborating to improve future directions in H&N cancer care**
Latrobe Ballroom
- 11:00am Collaborating to improve outcomes in recurrent and metastatic HNSCC
Prof Renata Ferrarotto
- 11:20am Common crimes in head and neck cancer surgical research and how to avoid them
Prof Hisham Mehanna
- 11:40am The importance of identification and management of lymphoedema for improving QOL
Prof Heather Starmar
- 12:00pm Debate: What matters more in laryngectomy management, the treatment team or the rehab team?
- 12:30pm ANZHNCS ASM 2025
Prof Eng Ooi
- 12:35pm Presentation of awards
Dr Kevin Nguyen
- 1:00pm - 5:00pm **Post-Meeting Workshop: Custom Silicone Colour Matching for Facial Prosthetics**
TBC, Melbourne

Hosted by  **BioMeDent.**
Specialist Dental & Medical Solutions

Sophie Fleming



NUCALA NOW PBS-LISTED FOR PATIENTS WITH CRSwNP^{1,2}

NUCALA is indicated as add-on treatment in adults with severe CRSwNP with an inadequate response to intranasal corticosteroids²

✓ **NUCALA on-treatment AEs similar to placebo (82% vs. 84%)³**

FIRST AND ONLY ANTI-IL-5 WITH PROVEN EFFICACY IN RECURRING, SEVERE CRSwNP^{2,4}
*Change from baseline in NPS and nasal obstruction VAS score at week 52

NOW PBS-LISTED

NUCALA
mepolizumab

Please review [PRODUCT INFORMATION](#) before prescribing.

PBS Information: The 100 mg/mL pen is listed on the PBS as a Section 100 item for CRSwNP. Refer to the PBS schedule for full authority information.

AE, adverse event; CRSwNP, chronic rhinosinusitis with nasal polyps; IL, interleukin; NPS, nasal polyp score; PBS, Pharmaceutical Benefits Scheme; VAS, visual analogue scale. **References:** 1. Pharmaceutical Benefits Scheme www.pbs.gov.au; 2. Nucala Product Information; 3. Han JK et al. Lancet Respir Med 2021;9(10):1141-53; 4. Severe Asthma Toolkit. Monoclonal antibodies (updated 2022 Oct 27; accessed 2023 Mar 3). Available from: toolkit.severeasthma.org.au/medications/monoclonal-antibodies. ©2023 GSK group of companies or its licensors. Trade marks are owned by or licensed to the GSK group of companies. GlaxoSmithKline Australia Pty Ltd, Melbourne, VIC. PM-AU-MPL-ADV-T-230001. Date of approval: April 2023.

ANZHNCs ASM 2024



AUSTRALIAN AND NEW ZEALAND
HEAD & NECK
CANCER SOCIETY

Collaborating to Redefine the Landscape of Head & Neck Cancer Care

Australian and New Zealand Head & Neck Cancer Society
25th Annual Scientific Meeting

29 – 31 August 2024

Sofitel Melbourne on Collins **Melbourne Australia**

MEETING ORGANISERS

Conferences & Events Management
Royal Australasian College of Surgeons
College of Surgeons Gardens
250 – 290 Spring Street
East Melbourne VIC 3002
Australia

T: +61 3 9249 1150
E: anzhnscs.asm@surgeons.org